FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2883005533> ?p ?o ?g. }

• W2883005533 endingPage "233" @default.
• W2883005533 startingPage "228" @default.
• W2883005533 abstract "Brivaracetam (BRV) is a high-affinity synaptic vesicle glycoprotein 2A ligand that is structurally related to levetiracetam (LEV). Compared to LEV, its affinity to the ligand is >10%-30% higher. Due to its more lipophilic characteristics, it might have a quicker penetration across the blood-brain barrier and potentially also a stronger anticonvulsant effect. Thus, we aimed to explore its usefulness in the treatment of status epilepticus (SE). We retrospectively assessed treatment response and adverse events in adjunctive treatment with intravenous BRV in patients with SE from January 2016 to July 2017 at our institution. Seven patients aged median 68 years (range = 29-79) were treated with intravenous BRV. Three patients had SE with coma and four without. SE arose de novo in two patients; etiology was remote symptomatic in four patients and progressive symptomatic in one patient. The most frequent etiology was remote vascular in two patients. BRV was administered after median four antiepileptic drugs (range = 2-11). Time of treatment initiation ranged from 0.5 hours to 105 days (median = 10.5 hours). Immediate clinical and electrophysiological improvement was observed in two patients (29%). Median loading dose was 100 mg intravenously over 15 minutes (range = 50-200 mg), titrated up to a median dose of 100 mg/d (range = 100-300). Median Glasgow Outcome Scale score was 3 (range = 3-5), with an improvement in 86% of patients compared to admission. We observed no adverse events regarding cardiorespiratory function. BRV might have potential as a novel antiepileptic drug in early stages of SE. Its potential may lie its ability to cross the blood-brain barrier more quickly than LEV and its favorable safety profile. Prospective studies for the use of BRV in SE are required." @default.
• W2883005533 created "2018-08-03" @default.
• W2883005533 creator A5002346029 @default.
• W2883005533 creator A5013414267 @default.
• W2883005533 creator A5021502726 @default.
• W2883005533 creator A5026432195 @default.
• W2883005533 creator A5043985426 @default.
• W2883005533 creator A5047061480 @default.
• W2883005533 creator A5061879826 @default.
• W2883005533 creator A5076045134 @default.
• W2883005533 creator A5077328801 @default.
• W2883005533 creator A5087184831 @default.
• W2883005533 date "2018-07-25" @default.
• W2883005533 modified "2023-10-15" @default.
• W2883005533 title "Intravenous brivaracetam in status epilepticus: A retrospective single‐center study" @default.
• W2883005533 cites W1492512073 @default.
• W2883005533 cites W1659275768 @default.
• W2883005533 cites W1856414226 @default.
• W2883005533 cites W1979898183 @default.
• W2883005533 cites W1992916966 @default.
• W2883005533 cites W2007191684 @default.
• W2883005533 cites W2012318617 @default.
• W2883005533 cites W2019957633 @default.
• W2883005533 cites W2051013481 @default.
• W2883005533 cites W2052474013 @default.
• W2883005533 cites W2065885918 @default.
• W2883005533 cites W2095271866 @default.
• W2883005533 cites W2131888662 @default.
• W2883005533 cites W2190040512 @default.
• W2883005533 cites W2198063087 @default.
• W2883005533 cites W2512614790 @default.
• W2883005533 cites W2607319988 @default.
• W2883005533 cites W2613020156 @default.
• W2883005533 doi "https://doi.org/10.1111/epi.14486" @default.
• W2883005533 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30043427" @default.
• W2883005533 hasPublicationYear "2018" @default.
• W2883005533 type Work @default.
• W2883005533 sameAs 2883005533 @default.
• W2883005533 citedByCount "43" @default.
• W2883005533 countsByYear W28830055332018 @default.
• W2883005533 countsByYear W28830055332019 @default.
• W2883005533 countsByYear W28830055332020 @default.
• W2883005533 countsByYear W28830055332021 @default.
• W2883005533 countsByYear W28830055332022 @default.
• W2883005533 countsByYear W28830055332023 @default.
• W2883005533 crossrefType "journal-article" @default.
• W2883005533 hasAuthorship W2883005533A5002346029 @default.
• W2883005533 hasAuthorship W2883005533A5013414267 @default.
• W2883005533 hasAuthorship W2883005533A5021502726 @default.
• W2883005533 hasAuthorship W2883005533A5026432195 @default.
• W2883005533 hasAuthorship W2883005533A5043985426 @default.
• W2883005533 hasAuthorship W2883005533A5047061480 @default.
• W2883005533 hasAuthorship W2883005533A5061879826 @default.
• W2883005533 hasAuthorship W2883005533A5076045134 @default.
• W2883005533 hasAuthorship W2883005533A5077328801 @default.
• W2883005533 hasAuthorship W2883005533A5087184831 @default.
• W2883005533 hasBestOaLocation W28830055331 @default.
• W2883005533 hasConcept C118552586 @default.
• W2883005533 hasConcept C126322002 @default.
• W2883005533 hasConcept C137627325 @default.
• W2883005533 hasConcept C167135981 @default.
• W2883005533 hasConcept C17624336 @default.
• W2883005533 hasConcept C197934379 @default.
• W2883005533 hasConcept C2775858608 @default.
• W2883005533 hasConcept C2777332695 @default.
• W2883005533 hasConcept C2777341932 @default.
• W2883005533 hasConcept C2778186239 @default.
• W2883005533 hasConcept C2780073493 @default.
• W2883005533 hasConcept C42219234 @default.
• W2883005533 hasConcept C71924100 @default.
• W2883005533 hasConceptScore W2883005533C118552586 @default.
• W2883005533 hasConceptScore W2883005533C126322002 @default.
• W2883005533 hasConceptScore W2883005533C137627325 @default.
• W2883005533 hasConceptScore W2883005533C167135981 @default.
• W2883005533 hasConceptScore W2883005533C17624336 @default.
• W2883005533 hasConceptScore W2883005533C197934379 @default.
• W2883005533 hasConceptScore W2883005533C2775858608 @default.
• W2883005533 hasConceptScore W2883005533C2777332695 @default.
• W2883005533 hasConceptScore W2883005533C2777341932 @default.
• W2883005533 hasConceptScore W2883005533C2778186239 @default.
• W2883005533 hasConceptScore W2883005533C2780073493 @default.
• W2883005533 hasConceptScore W2883005533C42219234 @default.
• W2883005533 hasConceptScore W2883005533C71924100 @default.
• W2883005533 hasIssue "S2" @default.
• W2883005533 hasLocation W28830055331 @default.
• W2883005533 hasLocation W28830055332 @default.
• W2883005533 hasOpenAccess W2883005533 @default.
• W2883005533 hasPrimaryLocation W28830055331 @default.
• W2883005533 hasRelatedWork W2005935329 @default.
• W2883005533 hasRelatedWork W2050711372 @default.
• W2883005533 hasRelatedWork W2057603779 @default.
• W2883005533 hasRelatedWork W2063505679 @default.
• W2883005533 hasRelatedWork W2076021110 @default.
• W2883005533 hasRelatedWork W2089616726 @default.
• W2883005533 hasRelatedWork W2765717291 @default.
• W2883005533 hasRelatedWork W2808260436 @default.
• W2883005533 hasRelatedWork W2988267881 @default.
• W2883005533 hasRelatedWork W4281625778 @default.

• next